|
Clinical features
|
Phase I
|
Phase II
|
Combined
|
|---|
|
sALS (n = 371)
|
Control (n = 711)
|
sALS (n = 300)
|
Control (n = 1076)
|
sALS (n = 671)
|
Control_2 (n = 1787)
|
|---|
|
Sex, M/F (ratio)
|
227/144 (1.58:1)
|
283/428 (0.66:1)
|
183/117 (1.56:1)
|
453/623 (0.73:1)
|
410/261 (1.57:1)
|
736/1051 (0.70:1)
|
|
Age (year, mean ± SD)
|
55.13 ± 10.28
|
69.41 ± 8.42
|
55.16 ± 9.82
|
69.83 ± 7.70
|
55.14 ± 9.97
|
69.66 ± 7.91
|
|
Age at onset (year, mean ± SD)
|
53.42 ± 10.28
|
–
|
53.49 ± 9.56
|
–
|
53.45 ± 9.96
|
–
|
|
Site of onset, bulbar (%)
|
73/371 (19.68%)
|
–
|
59/300 (19.61)
|
–
|
132/671 (19.67%)
|
–
|
- sALS, sporadic amyotrophic lateral sclerosis; AAO, age at onset
